Recurrence of Sydenham's Chorea
Uploaded by
onuraytop180Recurrence of Sydenham's Chorea
Uploaded by
onuraytop180Common questions
Powered by AIThe recurrence of Sydenham's chorea is defined as the re-emergence of chorea at least two months after the first episode, lasting more than 24 hours . Factors contributing to recurrence include irregular antibiotic prophylaxis, an inability to achieve remission within six months, symptoms persisting longer than one year, and possibly a permanent subclinical damage to the basal ganglia following the initial episode .
Sydenham's chorea is primarily distinguished in clinical diagnosis by its association with previous Group A beta-hemolytic streptococcal infection and as a major diagnostic criterion of acute rheumatic fever . Characteristic clinical features include chorea, hypotonia, dysarthria, and emotional lability, with chorea initially possibly presenting unilaterally and becoming generalized . For differential diagnosis, it must be differentiated from systemic lupus erythematosus-associated chorea, drug-induced chorea, hyperthyroidism, Wilson's disease, and PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections). T2-weighted cranial MRI hyperintensity in the putamen and globus pallidus, which disappears with disease improvement, also aids differentiation .
The historical presentation and treatment history of a child with Sydenham's chorea influence their current management strategy by providing insights into the disease progression, effectiveness of past treatments, and potential risk for recurrence. For a child previously treated with haloperidol and showing treatment unresponsiveness, alternative medications like valproic acid may be chosen, considering past efficacy and side effects . Additionally, regular antibiotic prophylaxis based on past adherence and streptococcal infection history remain critical to prevent recurrence and guide ongoing patient management .
In diagnosing a recurrence of Sydenham's chorea, neurological examination findings, such as involuntary choreiform movements, hypotonia, and a "milkmaid's grip," along with laboratory test results displaying slightly elevated antistreptolysin-O (ASO) titers, provide a comprehensive picture for diagnosis . While the ASO titer can indicate a recent streptococcal infection, the specific movement disorder symptoms confirm the clinical picture of chorea. Normal results in glucose, liver, and kidney function tests further support the diagnosis by excluding other potential causes .
Irregular antibiotic prophylaxis is identified as a risk factor for recurrence in Sydenham's chorea because it may fail to prevent further streptococcal infections, which can trigger additional autoimmune responses leading to recurrence . This implies that consistent and long-term antibiotic prophylaxis is crucial in patient management to maintain remission and minimize the risk of recurrence, emphasizing adherence to prescribed prophylactic regimens .
Understanding neurotransmitter imbalances, particularly the increased dopaminergic activity and decreases in acetylcholine and gamma-aminobutyric acid levels, is crucial for developing effective treatment strategies for Sydenham's chorea, as it directly informs the choice of medications that can counteract these imbalances . For example, the use of neuroleptic drugs aims to reduce excessive dopaminergic activity, while antiepileptic drugs help stabilize overall neurotransmitter levels. This tailored approach can enhance the quality of symptom management and offer a more focused treatment regimen .
A high ASO titer in the context of Sydenham's chorea implies a recent streptococcal infection, which is critical in establishing the connection between the infection and the autoimmune disorder . This relationship guides disease management by indicating the need for antibiotic therapy to manage any lingering infection and by reinforcing the importance of prophylactic antibiotics to prevent future infections that could cause recurrence .
Antiepileptic and neuroleptic drugs play a role in the treatment of Sydenham's chorea by modulating neurotransmitter levels within the basal ganglia, thus addressing the neurological imbalances characterizing the disorder . These drugs can reduce dopaminergic activity and stabilize the imbalance between the dopaminergic and cholinergic systems, which helps control involuntary movements associated with chorea . For instance, drugs like valproic acid decrease mood instability and involuntary movement rates, while haloperidol and pimozide manage symptoms by reducing dopamine levels .
Recommended treatment strategies for Sydenham's chorea include the use of antiepileptic drugs such as valproic acid and carbamazepine, neuroleptic agents like pimozide and haloperidol, and benzodiazepines to manage symptoms . Immunotherapies, including corticosteroids, intravenous immunoglobulins, and plasmapheresis, may be used for selected patients . High-dose penicillin treatment for 10 days is advised for active streptococcal infection, followed by prophylactic penicillin until age 21 to prevent recurrence .
The key autoimmune mechanism involved in the development of Sydenham's chorea is the cross-reaction between antibodies against streptococcal antigens produced following Group A beta-hemolytic streptococcal infections and basal ganglia antigens in genetically susceptible children . Neurologically, this results in an imbalance between the dopaminergic and cholinergic systems, leading to involuntary movements characteristic of chorea. Specifically, reductions in gamma-aminobutyric acid and acetylcholine levels alongside increased dopaminergic activity in the basal ganglia explain the disorder's symptoms .